Insulin (medication)
Top View
- Low Cost Options for Treating Type 2 Diabetes Mellitus
- Dasiglucagon a Novel Glucagon Analog Phase II Update
- Insulin-Secreting Non-Islet Cells Are Resistant to Autoimmune Destruction (Transgenic Models/Diabetes/Intermediate Pituitary/Insulin Gene Expression) MYRA A
- Insulin Aspart PI
- ACCEPTABLE COMBINATIONS of DIABETES MEDICATIONS (Updated 01/27/2021)
- (In Addition to Insulin) in Overweight Patients with Type‐1 Diabetes
- Lantus (Insulin Glargine)
- Human Placental Lactogen Administration in the Pregnant Rat: Acceleration of Fetal Growth
- Exenatide Appears to Be the Eti- Sessing Insulin Sensitivity from the Oral Polyposis
- Less Hypoglycemia with Insulin Glargine in Intensive Insulin Therapy for Type 1 Diabetes
- Insulin Access and Affordability Working Group
- BYETTA (Exenatide) Injection Hemodialysis and Kidney Transplantation
- Albiglutide (TANZEUM) Drug Monograph
- TANZEUM™ (Albiglutide) for Injection, for Subcutaneous Use
- Label and the Instructions for Use
- LIXISENATIDE and Iglarlixi (Insulin Glargine/Lixisenatide Fixed-Ratio Combination)
- ISMP Guidelines for Optimizing Safe Subcutaneous Insulin Use in Adults Table of Contents
- Ryzodeg, INN-Insulin Degludec/Insulin Aspart